Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Clinical and Laboratory Investigations

Helicobacter pylori and Behçet’s Disease

Avcı O.a · Ellidokuz E.b · Şimşek I.b · Büyükgebiz B.c · Güneş A.T.a

Author affiliations

Departments of aDermatology, bInternal Medicine and cPediatrics, Medical Faculty, Dokuz Eylül University, Inciralti, Turkey

Related Articles for ""

Dermatology 1999;199:140–143

Do you have an account?

Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Clinical and Laboratory Investigations

Published online: October 22, 1999
Issue release date: 1999

Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 2

ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)

For additional information: https://www.karger.com/DRM

Abstract

Background: Recent investigation of the etiology of Behçet’s disease (BD) has focused on heat shock proteins (HSP) which belong to the HSP 60 family. Both the gastric pathogen Helicobacter pylori (HP) and BD may cause ulcers in the gastrointestinal tract and, HP expresses HSP 60. Objective: Whether HP is linked to the pathogenesis of BD or not, and to investigate the influence of HP eradication on clinical parameters of BD. Methods: Patients with BD were divided into two groups. Group I comprised 49 patients and was investigated for HP seroprevalence and compared with age- and sex-matched controls. Group II comprised 20 patients with BD and HP infection diagnosed by serological and endoscopic examinations as well as the rapid urease test (RUT). A 1-week eradication therapy was administered for HP infection. Patients were examined for the course of BD at monthly intervals. Two months after the eradication therapy, patients underwent an endoscopic examination and RUT for eradication control. Seven patients were excluded because of eradication failure. Thirteen patients were evaluated for the influence of HP eradication on clinical manifestations of BD. The number and size of oral and genital ulcers before the eradication and at the end of the follow-up period were compared statistically. Results: HP seroprevalence between patients with BD and controls did not show significant difference. In 13 patients with BD, the number and size of oral and genital ulcers diminished significantly and various clinical manifestations regressed after the eradication of HP. Conclusion: HP may be involved in the pathogenesis of BD.


References

  1. Hamzaoui K, Ayed Kh, Hamza M, Touraine JL: Natural killer cells in Behçet’s disease. Clin Exp Immunol 1988;71:126–131.
  2. Hasan A, Fortune F, Wilson A, Warr K, Shinnick T, Mizushima Y, van der Zee R, Stanford MR, Sanderson J, Lehner T: Role of gamma delta T cells in pathogenesis and diagnosis of Behçet’s disease. Lancet 1996;347:789–794.
  3. Kaneko S, Suzuki N, Yamashito N, Nagafuchi H, Nakajima T, Wakisaka S, Yamamoto S, Sakane T: Characterization of T cells specific for an epitope of human 60-kD heat shock protein (hsp) in patients with Behçet’s disease in Japan. Clin Exp Immunol 1997;108:204– 212.
  4. Lehner T: The role of heat shock protein, microbial and autoimmune agents in the aetiology of Behçet’s disease. Int Rev Immunol 1997;14: 21–32.
  5. Stanford MR, Kasp E, Whiston R, Hasan A, Todryk S, Shinnick T, Mizushima Y, Dumonde DC, van der Zee R, Lehner T: Heat shock protein peptides reactive in patients with Behçet’s disease are uveitogenic in Lewis rats. Clin Exp Immunol 1994;97:226–231.
    External Resources
  6. Huesca M, Borgia S, Hoffman P, Lingwood CA: Acidic pH changes receptor bindings specificity of Helicobacter pylori: A binary adhesion model in which surface heat shock (stress) proteins mediate sulfatide recognition in gastric colonization. Infect Immunol 1996; 64:2643–2648.
  7. Yamaguchi H, Osaki T, Taguchi H, Hanawa T, Yamamoto T, Kamiya S: Induction and epitope analysis of Helicobacter pylori heat shock protein. J Gastroenterol 1996;31(suppl 9):12–15.
  8. International Study Group for Behçet’s disease: Criteria for diagnosis of Behçet’s disease. Lancet 1990;335:1078–1080.
  9. Direskeneli H, Hasan A, Shinnick T, Mizushima R, van der Zee R, Fortune F, Stanford MR, Lehner T: Recognition of B-cell epitopes of the 65 kDa HSP in Behçet’s disease. Scand J Immunol 1996;43:464–471.
    External Resources
  10. Engstrand L, Scheynius A, Pahlson C: An increased number of gamma/delta T-cells and gastric epithelial cell expression of the groEL stress-protein homologue in Heliobacter pylori associated chronic gastritis of the antrum. Am J Gastroenterol 1991;86:976–980.
  11. Heatley RC: Maastricht consensus report: Dual publication. Gut 1997;41:8–13.
  12. Duggan AE, Tolley K, Hawkey CJ, Logan RF: Varying efficacy of Helicobacter pylori eradication regimens: Cost effectiveness study using a decision analysis model. Br Med J 1998;316: 1648–1654.
  13. Ellidokuz E, Akpınar H, Ellidokuz H, SŞimsşek I, Okan A, Tankurt E, Gönen Ö, Aksakoğlu G: Meta-analysis of efficacy of PPI, amoxicillin, clarithromycin for Helicobacter pylori eradication in Turkey. Digestion 1998;59(suppl 3): 397.

Article / Publication Details

First-Page Preview
Abstract of Clinical and Laboratory Investigations

Published online: October 22, 1999
Issue release date: 1999

Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 2

ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)

For additional information: https://www.karger.com/DRM


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.